Anders Edvell is a Doctor of Medicines (MD), specialized in pharmaceutical medicines (University of Basel). He also holds a PhD in Cell biology and Histology, as well as an MBA from Stockholm School of Economics.
Anders is a board member of the Swedish Pharmaceutical Insurance company (LFF). Before joining Immedica he was the CEO of Unimedic Group (a regional Specialty pharma company with CDMO capabilities. Anders has a long-standing experience from working internationally with niche and rare diseases in companies such as Recip, Swedish Orphan and Sobi (where he established and developed the SPP division). He has also worked with global medical affairs at BMS.
Nina Fleck graduated with an LL.M. (Masters of Law) from Stockholm University in 2003.
Prior to joining Immedica, Nina worked as Senior Legal Counsel and as Vice President of Business Development at Swedish Orphan Biovitrum between 2003 and 2018
Håkan Garpenstrand holds a DDS degree from Karolinska Institutet, an executive MBA from Mgruppen in Stockholm, a PhD (medical doctor) from Uppsala university, where he since 2002 is also associate professor in pharmacology.
Prior to Immedica, Håkan was the vice president and head of corporate development at Sobi. In 2010-2011 he was head of commercial operations at Pfizer Sweden, and during 2007-2010, with bases in London and Stockholm, he held senior business development positions at Wyeth. 2002-2006 he operated in senior R&D management positions at Biovitrum.
Håkan has served on the boards of pharma companies Releef, Cywell, and ParkCell. He is currently a member of the advisory board of Salipro Biotech AB.
Carl brings extensive experience of commercializing niche specialty pharmaceuticals and orphan drug products in Europe and in the Middle East gained over 20 years.
Prior to Immedica, Carl held the position of Vice President Strategic Transactions at Sobi, and previously held several senior commercial positions including Vice President, Head of Partner Products at Sobi, Commercial Lead at Sobi, and Director of Sales at IMS health. Carl has also held several management positions in sales and marketing at Bristol-Myers Squibb. Carl has a Master of Business Administration from Stockholm Business School, Stockholm University.
Carina Carlsson is the Head of Quality and Responsible Person on company wholesaler license. Carina graduated with an M.Sc. in Pharmacy from Uppsala University in 1996.
Prior to Immedica, Carina was acting as Senior Director Quality Assurance, QP/RP, at Sobi between 2011-2018. Between 2003 to 2011 Carina acted as Head of Quality at ACO Hud Nordic and Swedish Orphan. Carina has more than 20 years’ experience in the Pharma Industry with focus on products manufactured on contract including supply and worldwide distribution.
Arvid Cronlund is the Head of the Drug Safety department and EU-Qualified Person for Pharmacovigilance for Immedica Pharma. He has an M.Sc in Pharmacy from Uppsala University in 1998. Arvid has 20 years of experience from Drug Safety in the Pharma industry.
Prior to Immedica he has been the Head of Drug Safety at Pfizer in Sweden and the Head of Drug Safety / EU-QPPV for Swedish Orphan Biovitrum (Sobi). Arvid has engaged in several pharmacovigilance networks including the Swedish Pharmaceutical Industry Association, EFPIA and the Swedish Pharmaceutical Society.
Susanne joined Immedica Pharma (Medical Need) from the start in 2011 as a manager of logistics, communication and customer service. Her background is in project managing, communication and in customer service. From 2017 her focus is communication.
Prior to this position Susanne was at Centre for business and policy studies (SNS) for 8 years where she was responsible for educational programs, forums and networks in the area of Economic politics.
Tomas Gloveus joined Immedica Pharma (Medical Need) in 2015 and is today General Manager Northern Europe. Tomas graduated with a Bachelor of Economics from University of Linköping in 1984.
Prior to joining Immedica Pharma Tomas served as General Manager for Genzyme in Sweden 2010 – 2014.
He has also been General Manager Northern Europe in Orion and General Manager in English speaking Africa in Aventis based in South Africa among other managerial positions.
Julia holds a degree of Master of Science in Business and Economics from Lulea University of Technology.
Prior to Immedica, Julia has been working as an Auditor at Grant Thornton between 2015 and 2017.
Louise Mehkri joined Immedica in 2018. Louise graduated with an M.Sc in Economics and Business from Stockholm School of Economics in 2002.
Louise has over 15 years’ experience within the Pharma Industry. Prior to joining Immedica, Louise worked as a International Brand Portfolio Director within the field of Specialty Care at Sobi where she also built strong capabilities in Alliance Management (2014 – 2018). Prior to that, Louise has extensive experience from different commercial positions at Pfizer, Wyeth and Astra Zeneca.
Lia started her career at the Swedish Medicinal Products Agency, but since 2003 she has been in the pharmaceutical industry within the field of regulatory affairs and quality assurance.
Prior to Medical, Lia was Director Regulatory Affairs at Medivir AB. Lia has also worked at Abbvie, BioPhausia and Swedish Orphan. Lia holds a M Sc Pharm from the University of Uppsala.